Trial
NCT07208760
L9LS-R21 Interaction
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
National Institutes of Health (NIH); Malaria Research and Training Center, Bamako, Mali; Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS); University of Sciences, Techniques, and Technologies of Bamako (USTTB); University of Washington; Indiana University
Condition
Malaria
Intervention
Single dose of 1800 mg L9LS SC (12mL)
Why stopped
After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-09